Table 2. NCATS components.

Programs that will be incorporated into or managed by NCATS (excepting CAN, which has not yet been funded) together represent ~$720 million annually in research support.

ProgramDescriptionContributions or expertises
CTSA program (48)Infrastructure grants awarded to academic medical institutions to facilitate translational researchNetwork of 60 U.S. centers with expertise in preclinical science, clinical trials, comparative effectiveness research, training, and community engagement
Components of the Molecular Libraries Program (58)Supports centers that provide access to large-scale screening, medicinal chemistry, and informatics for the identification of therapeutic and experimental chemical entitiesAssays development, high-throughput screening, medicinal chemistry, and compound databases
Therapeutics for Rare and Neglected Diseases (TRND) (59)A drug-development pipeline within the NIH used for research collaborations with academic scientists, nonprofit organizations, and companies working on rare and neglected illnessesPreclinical development of promising compounds
Rapid Access to Interventional Development (RAID) (60)A competitive granting program that provides resources for the development of new therapeutic agentsAccess to resources for preclinical development, production, bulk supply, GMP manufacturing, formulation, development of an assay suitable for pharmacokinetic testing, and animal toxicity
Office of Rare Diseases Research (61)A multifunctional NIH office that serves as a focal point for rare diseasesCoordination and support of research on rare diseases
NIH-FDA Regulatory Science Initiative (45, 46)A competitive grant program that funds regulatory scienceSupport of research on applicability of novel technologies and approaches to regulatory review of drugs, biologics, and devices
Cures Acceleration Network (CAN) (62)A competitive grant program to fund translational solutions to high-need medical problems; awaits appropriationSupport of translational research with greater flexibility to NIH to fund innovative research in therapeutic development